In what should come as no surprise to anyone who knows the effects of smoking on patients with asthma, a new report indicates that the latest strings of indoor smoking bans will have a direct impact on reducing emergency room visits due to asthma attacks. Basically, it proves that not subjecting children with breathing problems to tobacco smog is good for their health.
The study was done by researchers at the University of Chicago Medicine, Tech Times reports, and their findings indicate that the ban on smoking indoors results in the drastic reduction of asthma attacks among children that lead to emergency room visits. Three years after the ban was put in effect, ER visits were reduced by 17 percent.
Christina Ciaccio is an expert in pediatric allergy and along with her team, they looked into the emergency room records of over 20 cities where indoor smoking has been banned. After looking at their records from 2000 until 2014, the researchers noted a definite decrease in overall ER visits prompted by breathing problems among asthmatic patients.
This isn’t really surprising since air pollution of any kind has been a major hazard for the 6.3 million American children with asthma living in the U.S. alone. To be fair, other causes of asthma attacks can include everything from car exhaust, factory smoke, allergens, dust, and the occasional overexertion when the weather is cold.
However, as far as causes that induce attacks indoors go, smoking is cited as one of the leading factors, hence the ban. Then again, the researchers themselves acknowledge that their findings are not entirely foolproof since there are some fluctuations in data, MedicalXpress reports. For now, the results of the study simply show that the legislative action pertaining to the smoking ban has a significant impact on public health.


Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Novo Nordisk Appoints Greg Miley to Lead Corporate Affairs Amid U.S. Drug Pricing Pressure
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 



